Background
Akshaya J
Too sweet to be true? Prophylactic SGLT2 ...

MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.

Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery
Background
Cristina Adriana Popa
Buffering without benefit? The SODa-BIC study

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?

Buffering without benefit? The SODa-BIC study
Background
Pallavi Prasad
Beyond Diabetic Kidney Disease: FIND-ing ...

FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.

Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role
Background
Pallavi Prasad
On the right TRACK? Rivaroxaban to prevent ...

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Background
Cristina Adriana Popa
Heir to the Throne? Obinutuzumab in the ...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial

JAMA

MERCURI-2 on Instagram

MERCURI-2 on Instagram

A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Smita Divyaveer

Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery

Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery

MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

Track: El Resumen Visual

¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada?

El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en diálisis con alto riesgo cardiovascular.

Revisa nuestro más reciente resumen visual y acompáñanos en la próxima discusión de #NephJC.

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

This week, we will discuss the JAMA paper on disparities in living donor kidney transplant *rates* across race/ethnicities. There is a parallel paper from the UK, which shows somewhat similar findings. Join us Feb 6 and 7 to discuss on #NephJC!

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?